Amar Drawid, Ph.D. Email & Phone Number

Bernards, Nj, Us

Los Angeles, Ca, Us

• As Chief AI Officer, reinvented the 1,000+ FTE company into a Generative AI powerhouse by developing industry-leading portfolio of 30+ Generative AI and predictive analytics solutions across Commercial, Research, Development and Manufacturing. Implemented in multiple clients. • Established Innovation Lab as Center of Excellence (CoE) with 100+ Generative AI specialists. • Published white paper defining first-in-industry strategic framework for Life Science-specific Generative AI use cases about insight generation, novel content creation and invention of new biological entities. • Created Generative AI strategies and roadmaps for multiple clients to accelerate drug development and personalize customer experience. • Established Life Science Domain and Business Consulting function. Integrated them into front-end customer accounts and back-end operations. • Host of "Life Sciences DnA" video and audio podcasts discussing use of AI and data science with innovators in the biopharma industry. Available on YouTube and 8+ major podcast platforms.

Basel, Baselstadt, Ch

• Drove digital transformation by designing and implementing first-in-industry organization-wide data & digital strategy and innovative data science maturity scale based on commercial and medical business questions.• Spearheaded 50+ customer-centric enterprise solutions for (1) Insights and analytics: KPI framework, reporting, AI/ML, data strategy, platforms & governance, and (2) Sales and marketing ops: CRM, digital channels, content, marketing automation, consent management. Partnered with leads of IT, digital functions and business units.• Built diverse team of technical & business leaders; team received company’s top employee engagement score.• Shaped WW data-driven culture, organizations, operating models and governance by guiding country heads to drive business decisions using actionable insights. Designed change management and communication strategy.• Accelerated post-Covid digital interactions +900% to 60M total with 30K users in 100+ countries.• Developed WW data science, MarTech omnichannel product framework for next-gen customer engagement.• Created innovative end-to-end KPI framework to measure competitive selling of MarTech products based on value realization & sales model.• Expanded responsibilities to Medical Affairs (in addition to Commercial) & built trusted relations with its leadership.

Summit, New Jersey, Us

• As Chief Data Officer of $9B Oncology-Hematology franchise, implemented transformational vision to drive commercial decisions, marketing automation and digitization for 3 blockbuster inline brands and 9 launches using analytics & actionable insights.• Established strategic initiatives such as launch excellence framework, data & digital analytics strategy, end-to-end data & analytics governance, sales support model and stakeholder management.• Built 25-member team using hybrid model of customer-embedded personnel & Center of Excellence (internal, external, offshore). Inculcated “Think like a marketer” culture by coaching subordinate team leaders. Developed new offshore unit for scale. Created reputation as high-performing, business-focused proactive team by setting the culture and managing stakeholders.• Constructed big data cloud platform for AI apps and digital marketing with 100+ datasets in one year.• Revolutionized analytics by taking MarTech product approach, inventing pyramidal reporting strategy and partnering with franchises for design and promotion. Integral in C-suite’s decisions. 500,000 annual views.

Summit, New Jersey, Us

• Partnered with CFO on Juno & Bluebird Bio CAR-T cell therapy collaborations. Resulted in $9B Juno acquisition.• Changed investor guidance for blockbuster drug ABRAXANE’s forecast in lung, breast and pancreatic cancer. Overhauled lung cancer global brand plan and accurately predicted treatment landscape transformed by immuno-oncology (IO). • Shaped $1.4B PD-1 BeiGene deal and senior management’s IO partnership strategy with innovative analytics. • Created BD business cases for senior management in 14 tumor types by performing commercial analysis. Represented Celgene in interactions with partner companies’ C-level executives.• Steered clinical development to maximize commercial opportunity using financial forecasts.

Evanston, Il, Us

• Designed world’s first epidemiology model for predicting survival in multiple myeloma. Used by client CEO at JP Morgan conference to show value of innovation. Became first author on scientific posters, first in ZS’s history, published in premier oncology conferences. • Spearheaded 40+ projects worth $10M+ in forecasting, market research, marketing, real-world evidence (RWE), market access, business strategy, business development, portfolio strategy and analytics.• Led onshore & offshore team of 8-12 associates by coaching subordinate leaders. Expanded client-dedicated team.

Paris, France, Fr

• As translational medicine lead for clinical programs in inflammatory bowel disease and psoriasis, designed and implemented biomarker strategy by managing teams of ~25 members from labs and CROs in the US, France.• Directed biomarker-focused trials and translational medicine aspects of phase 1 and 2 trials. Authored trial protocols, amendments. Approved consent forms, case report forms, clinical study reports. Led site initiation visits. Approved consent forms, case report forms, clinical study reports. Guided statistical analysis plans. Orchestrated trial operations with logistics and data generation.• Received award for jump-starting a long-delayed clinical trial and re-establishing credibility with trial site.

Paris, France, Fr

• Led bioinformatics team of company’s largest research collaboration, worth $27M, with a premier immunology institute in France. Established company's first shared IT infrastructure.• Established bioinformatics strategy for target identification of biologics.• Constructed company’s first analytics portal with hands-on computer programming.• Invented computational methods for problems once considered unsolvable: (1) Comparison with 43 trillion protein sequences to determine freedom-to-operate for in-house antibodies, (2) Literature search method connecting thousands of diseases with thousands of genes to identify new orphan diseases for pipeline drugs, (3) “Biological back-screens” using chemistry, biology and statistics to increase hit rate 100-fold.• Drove phase transitions from target identification to lead generation for 50 immunology gene targets by analyzing large-scale genome sequencing and gene expression data.• Acted as “Translator” between biologists, IT and statisticians to deliver optimal results.

New Haven, Ct, Us

- Published 3 papers in such respected scientific journals as Journal of Molecular Biology, Trends in Genetics, and Genes and Development.- Developed a machine learning method to predict subcellular locations of yeast proteins. Included novel features such as gene expression and physical properties of proteins.

New Haven, Ct, Us

- Designed CGI, Perl scripts and maintained department web pages.

M.S., B.S., Bioinformatics, Computer Science, Molecular Biophysics And Biochemistry (Machine Learning)

Ph.D., Computational Biology & Molecular Biophysics (Artificial Intelligence / Machine Learning)